DAFTAR PUSTAKA
1. GLOBOCAN 2012 (IARC), Cervical Cancer, Estimated Incidence, mortality and prevalence Worldwide in 2012. Section of Cancer surveillance. 2012. [Diakses tanggal 21 Desember 2016]. Tersedia di: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.
2. World Health Organization (WHO). Comprehensive cervical cancer prevention and control: a healthier future for girls and women. WHO guidance note. 2013. Geneva: WHO Press. [Diakses tanggal 21
Desember 2016]. Tersedia di: http://www.who.int/immunization/hpv/learn/comprehensive_cervical_c
ancer_who_2013.pdf
3. Information Centre on HPV and Cancer (ICO-HPV Information Centre). Human Papillomavirus and Related Diseases in Indonesia. Summary Report. December 2016. [Diakses tanggal 24 Desember 2016]. Tersedia di http://www.hpvcentre.net/statistics/reports/XWX.pdf
4. Kementerian Kesehatan Republik Indonesia (RI). Situasi penyakit kanker. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. 2015. [Diakses tanggal 24 Desember 2016].
5. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2012;23:vii27-32.
6. Mabuchi S, Kawano M, Sasano T, Kuroda H. Management of early-stage and locally advanced cervical cancer. In: Shoupe D. Handbook of gynecology. Switzerland:Springer. 2016. p1-9.
7. Lee S-J, Kim J-H, Yoon J-H, Lee K-H, Park D-C, Kim C-J. Neoadjuvant Chemotherapy for Cervical Cancer: Rationale and Evolving Data. 2013. [Diakses tanggal 20 Januari 2017]. Tersedia di:
8. Bradbury M, Founta C, Taylor W, Kucukmetin A, Naik Raj, Ang C. Pathological risk factors and outcomes in women with stage IB2 cervical cancer treated with primary radical surgery versus chemoradiotherapy. Int J Gynecol Cancer. 2015;25:1476-83.
9. Wang H, Zhu L, Lu W, Xu H, Yu Y,Yang Y. Clinicopathological risk factors for recurrence after neoadjuvant chemotherapy and radical hysterectomy in cervical cancer. World Journal of Surgical Oncology. 2013;11:301
10. McCann GA, Taege SK, Boutsicaris CE, Philips GS, Eisenhauer EL, Fowler JM, O’Malley DM, et al. The impact of close surgical margins after radical hysterectomy for ealy-stage cervical cancer. Gynecol Oncol. 2013;128:44-8.
11. Moore DH. Review: Neoadjuvant chemotherapy for cervical cancer. Expert Opin. Pharmacother. 2003;4:859-67.
12. Robova H, Rob L, Halas MJ, Pluta M, Skapa P, Strnad P, et al. High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer. Gynecologic Oncology. 2013;128:49–53.
14. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Collab. 2010;1:1-25.
15. Wang Y, Wang G, Wei L-H, Wang J-L, Wang S-J, Li X-P. Neoadjuvant chemotherapy for locally advanced cervical cancer reduces surgical risks and lymph-vascular space involvement. Chin J Cancer. 2011;30: 645-52
16. Dasari SM, Tchounwou PB. Cisplatin in cancer therapy:molecular mechanisms of action. Eur J Pharmacol. 2014;0:364-78.
17. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003:22;7265-79.
18. Page R, Takimoto. Principles of chemotherapy. In: Padzur R, Coia LR, Hoskins WJ, Wagman LD. Cancer management: A multidisciplinary approach. Medical, surgical, and radiation Oncology. 7th eds. New York: The Oncology Group. 2003. p21-37.
19. Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, Lee JW, et al. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing
20. Ye Q, Yuan HX, Chen HL. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: A meta-analysis. J Cancer Res Clin Oncol. 2013;139:1887-98.
21. Ramez N, Eskander, Tawari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. 2014;6:280-92.
22. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncol. 2011;81:24-9.
23. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9:777-94.
25. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peter WA, et al. Markers of angiogenesis in high-risk, early stage cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2009;112:583-9.
26. Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in recurrent cervical cancer. Oncology Letters. 2010;1:3-11.
27. European Society for Medical Oncology (ESMO). Cervical cancer. 2012.[Diakses tanggal 21 Desember 2016]. Tersedia di:
28. Morshed K, Gruszka DP, Szymanski M, Dacewicz MP. Human papillomavirus (HPV)- Structure, epidemiology and pathogenesis. Otolaryngol Pol. 2014;150:1-7.
29. Vet JNI, de Boer MA, van den Akker BEWM, Siregar B, Lisnawati, Budiningsih S, et al. Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. British Journal of Cancer. 2008;99:214-8
30. Domingo EJ, Noviani R, Rushdan M, Ngelangel CA, Limpaphayom KK, Thuan TV, Louie KS, Quinn MA. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine. 2008;26S:M71-9.
31. Rasjidi I. Epidemiologi kanker serviks. Indonesian Journal of Cancer. 2009;3:104-6.
32. Shield TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG. A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human Papillomavirus.
Cancer Epidemol Biomarkers Prev. 2004;13:1574-80.
34. Schiffman M, Wentzensen N. Human papillomavirus (HPV) infection and the multi-stage carcinogenesis of cervical cancer. Cancer Epidemol Biomarkers Prev. 2013;22:553-60.
35. Gómez DT, Santos JL. Human papilloma virus infection and cervical cancer: pathogenesis and epidemiology. In: Vilas AM. Communicating Current Research and Educational Topics and Trends in Applied Microbiology. 2007. p680-8.
36. Hoffman BL, Schorge JO, Schaffer JI, Halvorson LM, Bradshaw KD, Cunningham FG. Cervical Cancer. Dalam: Williams Gynecology. Edisi ke-3. New York: McGraw-Hill. 2016. h.769-92.
37. Yan M, Zhang YN, He JH, Sun JR, Sun XM. Influence of lymph vascular space invasion on prognosis of patients with early-stage cervical squamous cell carcinoma. Chinese J Cancer. 2010;29:425-30.
38. Eurocytology. Cervical cytology (Up to date 2016). In: Pathogenesis of cervical cancer. Diakses tanggal 20 Januari 2017. Terdapat di:
39. Khan M, Diaz-Montes TP. Cervical cancer. In: Hurt KJ, Guile MW, Bienstock JL, Fox HE, Wallach EE. The John Hopkins manual of gynecology and obstetrics. 4th eds. Philadelphia: Lippincott Williams & Wilkins. 2011. p541-58.
40. Wiebe E, Denny L, Thomas G. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2012;119S2:S100-9.
41. Kementerian Kesehatan. Pedoman nasional pelayanan kedokteran (PNPK) : Kanker Serviks. Jakarta: Kementrian Kesehatan. 2015. h.1-65.
42. Vaupel P, Harrison L., Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004; 5:4-9.
44. Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, Panici PB, Tomao S. Angiogenesis and antiangiogenic agents in cervical cancer. OncoTargets and Therapy. 2014;7:2237-48.
45. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro- angiogenic therapies. Genes & Cancer. 2011;2:1097-105
46. Weis SM, Cheresh DA. Tumor Angiogenesis: molecular pathways and therapeutic targets. Nature Medicine. 2011;17:1359-64.
47. Senger DR, Davis GE. Angiogenesis. Cold Spring Harb Perspect Biol. 2011;3:1-19.
48. Bowden DJ, Barett T. Angiogenesis imaging in neoplasia. Journal of Clinical Imaging Science. 2011;1:1-7
49. Berek JS, Hacker NF. Biology and Genetics. Dalam: Gynecologic Oncology. Edisi ke-6. Wolters Kluwer. 2015. h.15-16.
50. Bielenberg D. Angiogenesis signaling pathway. 2014. Diakses tanggal
10 Januari 2017. Terdapat di:
51. Ziyad S, Iruela-Arispe ML. Molecular mechanism of tumor angiogenesis. Genes&Cancer. 2011;2:1085-96.
52. Schlieve CR, Mojica SG, Holoyda KA, Hou XG, Fowler KL, Grickscheit TC. Vascular endothelial growth factor (VEGF) bioavaibility regulates angiogenesis and intestinal stem and progenitor cell proliferation during postnatal small intestinal development. PloS One. 2016;11:1-28.
53. Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, Jung MH, Ock MS, Cha HJ. Elevated expression of thymosin β4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in early -stage cervical cancers. Pathol Oncol Res. 2011;17:493-502.
advanced cervical cancer: a randomized multicenter study. Gynecologic Oncology. 2016;141:231-9.
55. Sethasathein S, Charoenkwan K, Settakorn J, Srisomboon J. Predicting factor for positive vaginal surgical margin following radical hysterectomy for stage IB1 carcinoma of the cervix. Asian Pac J Cancer Prev. 2014;15:2211-5.
56. Sardi J, DiPaola GR, Cachau A, Ortiz OC, Sananes C, Giaroli A, et al. A possible new trend in the management of the carcinoma of the cervix uteri. Gynecology Oncology. 1986;25:139-49.
57. Eiriksson L, Miroshnichenko G, Covens A. Neoadjuvant chemotherapy in the treatment of cervical cancer. In: Bathe OF. Neoadjuvant chemotherapy: Current application in clinical practice. Croatia: In Tech. 2012. p81-108.
58. Florea A-M, Busselberg D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. 2011;3:1351-71.
59. Furlanut M, Franceshi L. Pharmacology of ifosfamide. Oncol. 2003;65:2-6.
60. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer. 2009;45:228-47.
61. Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development and Therapy. 2016:10;1885–95.
62. Peng HF, Xie K, Liu XJ. Dynamic monitoring of the changes of serum VEGF in cervical squamous cell carcinoma before and after chemotherapy. Practical Oncol J. 2010;24:546-9.
64. National Cancer Institute. NCI dictionary of cancer terms. DIakses tanggal 11 Januari 2017. Terdapat di:
65. Maae E, Nielsen M, Steffensen KD, Jakobsen EH, Jakobsen A, Sorensen FB. Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast. J Histochemist cytochemist. 2011;59:750-60.
66. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa T, Sunamori M, et al. Sex steroid hormone receptors in human thymoma. J Clinic Endocrinol Metabolism. 2003;88(5):2309-17.
67. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz APN, Metzger GJ, Schmechel SC. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagnos Pathol. 2012;7:1-10.
68. Qureshi A, Pervez S. Allred scoring for ER reporting and it’s impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc. 2010;60:350-3.
69. Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochemist Cytochemist. 2010;58:95-107.
70. Harvey JM, Remmele W, Goldhirsch A, Wolff AX. IVD certified breast cancer panel. Immunohistology Breast Pathology. 2013. p1-2. Available from : http://www.zytomed-systems.com/downloads/product-flyer/immunohistology/262-ivd-certified-breast-cancer-panel/file.html. [Accessed 11st January 2017]
71. Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP, Prasad V, Hommann M. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187-94.
– a review. Fedchenko and Reifenrath Diagnostic Pathology. 2014;9:1-12.
73. Westin MCA, Rabelo-Santos SH, Angelo-Andrade LAL, Derchain S, Pinto GA, Morais S, Filho PL, Zeferino LC. Expression of VEGF-A in intraepithelial and invasive cervical neoplasia. J Cytol Histol. 2015;22:1-5.
74. Kamus Besar Bahasa Indonesia (online) [diakses tanggal 29 Juni 2016]. Tersedia di:
